Risk-benefit assessment of IBD drugs: a physicians and patients survey

D’Amico, Ferdinando; Caron, Bénédicte; Vieujean, Sophie; Peyrin-Biroulet, Laurent; Danese, Silvio

Request a copy

Poster (Scientific congresses and symposiums)

Risk-benefit assessment of IBD drugs: a physicians and patients survey

D’Amico, Ferdinando; Caron, Bénédicte; Vieujean, Sophie et al.

2023 • 18th Congress of European Crohn's and Colitis Organisation 2023

Peer reviewed

Permalink
https://hdl.handle.net/2268/298941

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Abstract ECCO 23.docx

Author preprint (17.74 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Gastroenterology & hepatology

Author, co-author :

D’Amico, Ferdinando; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy > Department of Gastroenterology and Endoscopy

Caron, Bénédicte; University of Lorraine, Inserm, NGERE, F-54000 Nancy, France

Vieujean, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Peyrin-Biroulet, Laurent; University of Lorraine, Inserm, NGERE, F-54000 Nancy, France

Danese, Silvio; IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy > Department of Gastroenterology and Endoscopy

Language :

English

Title :

Risk-benefit assessment of IBD drugs: a physicians and patients survey

Publication date :

March 2023

Event name :

18th Congress of European Crohn's and Colitis Organisation 2023

Event date :

1-4 March, 2023

By request :

Yes

Audience :

International

Peer reviewed :

Peer reviewed

Available on ORBi :

since 16 January 2023

Statistics

Number of views

41 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics